Translate

Tuesday, October 17, 2017

thumbnail

MNKD MannKind Corporation gains 110% Oct 17, 2017

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California. http://www.priceseries.com/trade/MNKD-MannKind-Corporation-stock-gains-110-percent-a-Trade-Record-by-priceSeries-2017100220171017.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive